Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI), a leading global pharmaceutical consulting firm, has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds.
Due to the complex nature of a multitude of existing as well as newly-discovered active ingredients, solubility and bioavailability problems are inherent in the pharmaceutical industry causing major delays in drug development. Fortuitously, several novel drug delivery technologies can now be deployed to address solubility and bioavailability issues.
Technology Catalysts' newly released report on "Poorly Soluble and Poorly Permeable Drugs", identifies 30 poorly soluble drugs with low bioavailability recently launched in the US. TCI believes these drugs represent a huge business opportunity for specialty pharmaceutical, drug delivery, as well as generic companies using technologies that TCI has identified. TCI estimates the current sales of BCS Class IV oral solid dose drugs to be in excess of $145 billion.
In a recent conversation with TCI, Jane Nichols, Director of Business Development for Nanocopoeia, Inc., an innovative provider of nanosized API particles for enhancing drug solubility, stated "demand for novel drug delivery technologies and materials to improve solubility and permeability of drugs is only going to rapidly increase over time and Nanocopoeia, with our focus on particle based therapeutics, is poised to play a strong role in this field."
TCI's report describes in detail vital techniques such as solid dispersion, hot-melt extrusion, nanotechnology, and complexation to enhance solubility of many molecules. Permeability through the gastrointestinal tract is a rate limiting step for delivering macromolecules and very polar compounds. Examples of technologies specifically designed to solve these problems that are covered in the report include natural transporter systems, enzyme inhibition, and bioadhesion. Also discussed in the report is the use of gamma scintigraphy in combination with smart pills that has enabled a better understanding of the permeation of drugs in the GI tract.
The report provides key information such as water solubility, bioavailability, and 2012-2013 annual sales. Over 80 detailed descriptions of licensing and business opportunities for enhancing solubility and permeability discussed in the report provide a comprehensive understanding as well as vital solutions for overcoming these issues.
To download a complimentary excerpt of this report, go to: